Table 1 Demographics and clinical features of the enrolled patients a
Demographics and clinical features | Year 2007 | 2011 |
|---|---|---|
N (males) | 56 (32) | 72 (38) |
Age, years (mean ± SD) | 66 ± 10 | 69 ± 9 |
Disease duration, years (mean ± SD) | 3.5 ± 1.8 | 4.6 ± 1.4 |
Hoehn and Yahr stage (mean ± SD) | 1.8 ± 0.4 | 1.9 ± 0.3 |
UPDRS-III score (mean ± SD) | 20.8 ± 6.1 | 20.5 ± 6.5 |
Age <65 years, n (%) | 20 (35%) | 23 (32%) |
Age <65 years, UPDRS-III score (mean ± SD) | 19.7 ± 3.9 | 19.3 ± 5.1 |
Age between 65 and 75 years, N (%) | 30 (54%) | 31 (43%) |
Age between 65 and 75 years, UPDRS-III score (mean ± SD) | 20.1 ± 6.7 | 21.0 ± 5.9 |
Age >75 years, n (%) | 6 (11%) | 18 (25%) |
Age >75 years, UPDRS-III score (mean ± SD) | 23.9 ± 5.1 | 23.5 ± 4.6 |
High functional requirement, n (%) | 18 (32%) | 24 (33%) |
High functional requirement, UPDRS-III score (mean ± SD) | 20.2 ± 6.8 | 20.9 ± 5.9 |
Moderate functional requirement, n (%) | 20 (36%) | 19 (26%) |
Moderate functional requirement, UPDRS-III score (mean ± SD) | 22.1 ± 5.2 | 21.9 ± 4.8 |
Low functional requirements, n (%) | 18 (32%) | 29 (40%) |
Low functional requirement, UPDRS-III score (mean ± SD) | 24.1 ± 5.2 | 24.4 ± 4.9 |
Daily LD, monotherapy, mg (mean ± SD) | 328 ± 67 | 267 ± 62b |
Daily DA equivalents, monotherapy, mg (mean ± SD) | 237 ± 74 | 277 ± 62 |
Daily total LD equivalents, combined therapy, mg (mean ± SD) | 483 ± 133 | 440 ± 111 |
Daily DA equivalents, combined therapy, mg (mean ± SD) | 161 ± 80 | 177 ± 78 |
Daily LD, combined therapy, mg (mean ± SD) | 330 ± 72 | 263 ± 61b |
Side effects forcing reduction/withdrawal of DA therapy, n (%) | 7/37 (18.9%) | 7/57 (12.3%)c |